Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We use our state-of-the-art dedicated workflow for designing focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P62081

UPID:
RS7_HUMAN

ALTERNATIVE NAMES:
40S ribosomal protein S7

ALTERNATIVE UPACC:
P62081; P23821; P24818; Q57Z92; Q6IPH1

BACKGROUND:
The protein Small ribosomal subunit protein eS7, alternatively known as 40S ribosomal protein S7, is integral to the ribosome's function in protein synthesis. It ensures the proper maturation of rRNA and is a critical component of the SSU processome, facilitating RNA processing necessary for ribosomal assembly.

THERAPEUTIC SIGNIFICANCE:
Linked to Diamond-Blackfan anemia 8, Small ribosomal subunit protein eS7's involvement in this genetic disorder highlights its potential as a target for therapeutic intervention. Exploring the function of Small ribosomal subunit protein eS7 could lead to breakthroughs in treating this form of congenital non-regenerative hypoplastic anemia.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.